Mankind Pharma Ltd

Mankind Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Mankind Pharma Ltd

₹ 2,287 -1.22%
06 May - close price
mankindpharma.com BSE: 543904 NSE : MANKIND
About

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

Key Points

Leadership[1]

<h1>1 Rank in Prescriptions over the last 5 yrs.</h1> <h1>Youngest in Top 5 of the IPM</h1> <h1>4 By value in the IPM</h1> <h1>4 Consumer Healthcare brands Market ranked #1 in their categories</h1>
Website BSE NSE
  • Market Cap ₹ 91,628 Cr.
  • Current Price ₹ 2,287
  • High / Low ₹ 2,490 / 1,241
  • Stock P/E 53.0
  • Book Value ₹ 210
  • Dividend Yield 0.00 %
  • ROCE 22.4 %
  • ROE 18.4 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 10.9 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
1,726 2,180 2,426 2,091 2,053 2,579 2,708 2,607
1,441 1,724 1,835 1,654 1,636 1,924 2,025 2,000
Operating Profit 285 456 591 437 417 655 683 607
OPM % 16% 21% 24% 21% 20% 25% 25% 23%
39 20 31 40 50 63 63 75
Interest 13 16 10 13 5 6 9 9
Depreciation 47 78 79 85 85 87 96 110
Profit before tax 263 382 533 379 377 624 641 562
Tax % 27% 22% 21% 22% 22% 21% 20% 18%
193 298 423 296 294 494 511 460
EPS in Rs 4.75 7.30 10.48 7.09 7.13 12.15 12.51 11.33
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
3,334 5,865 6,214 7,782 8,749 9,946
2,748 4,427 4,565 5,791 6,848 7,586
Operating Profit 586 1,438 1,649 1,991 1,902 2,361
OPM % 18% 25% 27% 26% 22% 24%
76 122 183 210 141 252
Interest 2 23 21 60 46 29
Depreciation 39 99 119 167 326 378
Profit before tax 621 1,438 1,692 1,975 1,671 2,205
Tax % 29% 27% 24% 26% 22%
445 1,056 1,293 1,453 1,310 1,759
EPS in Rs 25.72 31.59 35.78 32.00 43.12
Dividend Payout % 0% 0% 24% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 14%
TTM: 18%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 8%
TTM: 46%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 24%
Last Year: 18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 20 40 40 40 40 40
Reserves 2,035 3,445 4,682 6,115 7,395 8,388
0 131 241 873 170 179
968 1,449 1,397 2,080 2,080 2,490
Total Liabilities 3,022 5,065 6,360 9,108 9,686 11,098
316 1,600 1,664 3,588 4,251 4,666
CWIP 47 317 372 701 550 159
Investments 959 829 1,512 1,109 1,346 2,041
1,700 2,319 2,811 3,709 3,538 4,233
Total Assets 3,022 5,065 6,360 9,108 9,686 11,098

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023
1,070 1,137 920 1,813
-436 -1,222 -1,369 -1,052
-531 -8 605 -740
Net Cash Flow 103 -92 156 22

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 22 33 19 18 24
Inventory Days 166 175 243 265 188
Days Payable 71 145 137 162 126
Cash Conversion Cycle 117 63 125 121 85
Working Capital Days 56 35 43 62 45
ROCE % 37% 32% 22%

Shareholding Pattern

Numbers in percentages

24 Recently
Jun 2023Sep 2023Dec 2023Mar 2024
76.50% 76.50% 76.50% 74.88%
4.18% 4.18% 6.74% 9.87%
4.65% 4.56% 9.78% 11.14%
14.67% 14.76% 6.97% 4.10%
No. of Shareholders 1,31,9181,34,7311,27,4491,35,116

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls